Related Experiment Videos
Mutational analysis of the beta-tubulin gene in lung cancer
Junji Tsurutani1, Takefumi Komiya, Hisao Uejima
1Fourth Department of Internal Medicine, Kinki University School of Medicine, Ohonohigashi 377-2, Osakasayama, 589-8511, Osaka, Japan.
Abstract:
Recently, several studies have suggested that a major mechanism of resistance to paclitaxel might involve mutations in the beta-tubulin gene in tumor cells. To investigate the frequency of beta-tubulin mutations in Japanese patients with small and non-small cell lung cancer, direct sequence analysis following reverse transcription-polymerase chain reaction (RT-PCR) of the beta-tubulin gene was performed using total RNA from 20 lung cancer cell lines and 22 specimens from lung cancer patients. First-strand cDNA sequence analysis of the 42 samples showed silent mutations at codon 180 of the beta-tubulin gene, which encodes the GTP-binding site of the protein, and codons 195 and 217. However, neither missense nor non-sense mutations affecting microtubule dynamics, within or near the GTP-binding site of the beta-tubulin gene, were detected. These results indicate that beta-tubulin gene mutations might not play a major role in the mechanism of resistance to paclitaxel in Japanese lung cancer patients. Further investigations are needed to clarify the mechanism of drug resistance.
Insights
Beta-tubulin gene mutations are not a primary cause of paclitaxel resistance in Japanese lung cancer patients. Researchers found only silent mutations, not those affecting drug efficacy, in analyzed samples.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Paclitaxel is a crucial chemotherapy agent for lung cancer.
- Tumor cell resistance to paclitaxel is a significant clinical challenge.
- Beta-tubulin gene mutations have been implicated as a potential resistance mechanism.
Purpose of the Study:
- To investigate the frequency and type of beta-tubulin gene mutations in Japanese lung cancer.
- To determine if these mutations contribute to paclitaxel resistance.
Main Methods:
- Direct sequence analysis of the beta-tubulin gene.
- Reverse transcription-polymerase chain reaction (RT-PCR) on RNA from lung cancer cell lines and patient specimens.
- Analysis of 42 samples (20 cell lines, 22 patient specimens).
Main Results:
- Silent mutations were detected at codons 180, 195, and 217 of the beta-tubulin gene.
- No missense or non-sense mutations affecting microtubule dynamics were found near the GTP-binding site.
- These findings suggest beta-tubulin mutations are not a major factor in paclitaxel resistance.
Conclusions:
- Beta-tubulin gene mutations do not appear to be a primary mechanism of paclitaxel resistance in this cohort of Japanese lung cancer patients.
- Further research is necessary to elucidate the exact mechanisms of paclitaxel drug resistance.